PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
28711499-5	2017	Our previous study found that Raloxifene inhibited IL-6/GP130 interaction, resulting in blockade of STAT3 phosphorylation.	Raloxifene Hydrochloride	30-40	interleukin 6 cytokine family signal transducer	Homo sapiens	56-61	
29714141-13	2019	Consistently, other IL-6/GP130 inhibitors SC144 and evista showed similar inhibition of IL-6 stimulated cell viability, cell proliferation and glycolysis.	Raloxifene Hydrochloride	52-58	interleukin 6 cytokine family signal transducer	Homo sapiens	25-30	
32940862-0	2021	Raloxifene inhibits pancreatic adenocarcinoma growth by interfering with ERbeta and IL-6/gp130/STAT3 signaling.	Raloxifene Hydrochloride	0-10	interleukin 6 cytokine family signal transducer	Homo sapiens	89-94	
28430601-4	2017	We reported the discovery of EVISTA (Raloxifene HCl) as novel inhibitor of IL-6/GP130 protein-protein interactions (PPIs) using multiple ligand simultaneous docking (MLSD) and drug repositioning.	Raloxifene Hydrochloride	37-51	interleukin 6 cytokine family signal transducer	Homo sapiens	80-85	
28430601-0	2017	Growth-suppressive activity of raloxifene on liver cancer cells by targeting IL-6/GP130 signaling.	Raloxifene Hydrochloride	31-41	interleukin 6 cytokine family signal transducer	Homo sapiens	82-87	
28430601-4	2017	We reported the discovery of EVISTA (Raloxifene HCl) as novel inhibitor of IL-6/GP130 protein-protein interactions (PPIs) using multiple ligand simultaneous docking (MLSD) and drug repositioning.	Raloxifene Hydrochloride	29-35	interleukin 6 cytokine family signal transducer	Homo sapiens	80-85	
28430601-12	2017	CONCLUSIONS: Our results suggest that Raloxifene is a potent IL-6/GP130 inhibitor and may be a chemoprevention agent for liver cancer by targeting persistent STAT3 signaling.	Raloxifene Hydrochloride	38-48	interleukin 6 cytokine family signal transducer	Homo sapiens	66-71	
24456369-0	2014	Drug design targeting protein-protein interactions (PPIs) using multiple ligand simultaneous docking (MLSD) and drug repositioning: discovery of raloxifene and bazedoxifene as novel inhibitors of IL-6/GP130 interface.	Raloxifene Hydrochloride	145-155	interleukin 6 cytokine family signal transducer	Homo sapiens	201-206	
24456369-2	2014	We report here the discovery of raloxifene and bazedoxifene as novel inhibitors of IL-6/GP130 protein-protein interactions (PPIs) using multiple ligand simultaneous docking (MLSD) and drug repositioning approaches.	Raloxifene Hydrochloride	32-42	interleukin 6 cytokine family signal transducer	Homo sapiens	88-93	
24456369-4	2014	Similarity searches of virtual hits on drug databases identified raloxifene and bazedoxifene as potential inhibitors of IL-6/GP130 interaction.	Raloxifene Hydrochloride	65-75	interleukin 6 cytokine family signal transducer	Homo sapiens	125-130